[A18-87] Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 20.06.2019
Project no.:
A18-87
Commission:
Commission awarded on 19.12.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Children and adolescents with highly active or rapidly evolving relapsing-remitting multiple sclerosis (RRMS)
If RRMS is highly active and switch of basic therapeutic agents is indicated despite a full and adequate course of treatment with at least one disease-modifying therapy: hint of non-quantifiable added benefit. Other patient groups: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-42 | Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87 | Commission completed |
| A11-23 | Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A15-48 | Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-21 | Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A15-12 | Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2019-06-20 A G-BA decision was published.